Factor VIII biosimilar (Chia Tai-Tianqing)

Product Name :
Factor VIII biosimilar (Chia Tai-Tianqing)

Search keywords :
Factor X

drugId :
null

Target Vo:
Coagulation factor X

Target Vo Short Name :
F10

Moa_Name:
Factor VIII replacements

First Approval Country :
Mainland China

First Approval Date Filter:
2023

Origin Company_Name :
Suzhou Alphamab Co Ltd

Active Company_Name :
Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group

Active Indication_Name:
Hemophilia A

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Approved

China Highest Status:
Approved

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Mitazalimab Data Sheet
TCF7L2/TCF4 Rabbit mAb Autophagy
SP7/Osterix Antibody: SP7/Osterix Antibody is an unconjugated, approximately 45 kDa, rabbit-derived, anti-SP7/Osterix polyclonal antibody. SP7/Osterix Antibody can be used for: WB, ELISA, IHC-P, IHC-F, IF expriments in human, mouse, and predicted: rat, dog, pig, cow, horse, rabbit background without labeling.

Author: Betaine hydrochloride

Related Posts